Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Short-term Investments (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Short-term Investments for 12 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 93.07% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Dec 2025, down 93.07%, and an annual FY2025 reading of $3.2 million, down 93.07% over the prior year.
  • Short-term Investments was $3.2 million for Q4 2025 at Karyopharm Therapeutics, down from $8.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $176.3 million in Q1 2023 and bottomed at $3.2 million in Q4 2025.
  • Average Short-term Investments over 5 years is $84.0 million, with a median of $72.2 million recorded in 2022.
  • The sharpest move saw Short-term Investments soared 274.2% in 2022, then plummeted 93.07% in 2025.
  • Year by year, Short-term Investments stood at $38.2 million in 2021, then skyrocketed by 274.2% to $142.8 million in 2022, then decreased by 2.5% to $139.2 million in 2023, then tumbled by 66.79% to $46.2 million in 2024, then tumbled by 93.07% to $3.2 million in 2025.
  • Business Quant data shows Short-term Investments for KPTI at $3.2 million in Q4 2025, $8.2 million in Q3 2025, and $13.0 million in Q2 2025.